BEIJING, April 28, 2025 /PRNewswire/ -- The China Electricity Council, TÜV Rheinland, China General Certification Center（CGC), AIKO, and LONGi jointly released the Back Contact (BC) Solar Technology Development White Paper (hereinafter referred to...
Read moreBEIJING, April 28, 2025 /PRNewswire/ -- The China Electricity Council, TÜV Rheinland, China General Certification Center（CGC), AIKO, and LONGi jointly released the Back Contact (BC) Solar Technology Development White Paper (hereinafter referred to...
Read moreHONG KONG, April 28, 2025 /PRNewswire/ -- In response to the urgent need for emotional health awareness among students, as highlighted in the Hong Kong Department of Health's "Student Health...
Read moreBEIJING, April 28, 2025 /PRNewswire/ -- Recently, BlueFocus released its 2024 Annual Report, recording a total revenue of RMB 60.797 billion for the year, marking a 15.55% year-on-year increase and...
Read moreSHENZHEN, China, April 28, 2025 /PRNewswire/ -- Lexar, a global consumer brand of data storage solutions conducted a 2-day media event participated by a select group of journalists from leading international...
Read moreSeeking collaboration partners to establish a manufacturing facility in U.S. for its lithium-ion battery solutionsParticipating in Advanced Clean Transportation Expo ("ACT Expo") event from 28 April to 1 May 2025...
Read moreBEIJING, April 28, 2025 /PRNewswire/ -- Recently, BlueFocus released its 2024 Annual Report, recording a total revenue of RMB 60.797 billion for the year, marking a 15.55% year-on-year increase and...
Read moreMUNICH, April 28, 2025 /PRNewswire/ -- Sungrow, the global leading PV inverter and energy storage system provider, announced that it won the 2025 iF Design Award for its flagship project,...
Read moreMUNICH, April 28, 2025 /PRNewswire/ -- Sungrow, the global leading PV inverter and energy storage system provider, announced that it won the 2025 iF Design Award for its flagship project,...
Read moreSUZHOU, China, April 28, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV")...
Read more
